Key facts
- Maxion Therapeutics’s last known valuation is $110.6M (Feb 2025).
- It has raised $105.1M; the latest was Later Stage VC ($89.2M) in Feb 2025.
- Notable investors include Innovate UK, General Catalyst, British Business Bank, BGF (Financial Services), Eli Lilly — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Maxion Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Maxion Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Maxion Therapeutics
Developer of a novel platform designed to generate antibody-like therapeutics to solve ion channel and GPCR-driven diseases. The company combines mini-proteins found in venom and other sources called knottins into the antibody surface to create mixtures while creating the optimum drug-like properties of antibodies, enabling patients with chronic pain, autoimmune, and cardiovascular diseases to access safe, long-lasting, and selective treatments.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2020
- Employees
- 50
- Website
- maxiontherapeutics.com/
- Ownership
- Privately Held (backing)
Maxion Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Maxion Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Maxion Therapeutics in its N-PORT filings yet. We sweep new filings monthly.